Stryker (NYSE:SYK) Issues Earnings Results, Beats Estimates By $0.14 EPS

Stryker (NYSE:SYK) released its quarterly earnings results on Tuesday. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14, Zacks reports. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker updated its FY 2025 guidance to 13.450-13.700 EPS.

Stryker Stock Down 1.2 %

SYK traded down $4.98 on Tuesday, hitting $394.92. The company had a trading volume of 1,992,456 shares, compared to its average volume of 1,494,289. Stryker has a 52-week low of $310.74 and a 52-week high of $406.19. The stock has a fifty day simple moving average of $376.32 and a 200-day simple moving average of $361.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market capitalization of $150.55 billion, a P/E ratio of 42.33, a P/E/G ratio of 2.68 and a beta of 0.95.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is currently 36.01%.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Citigroup raised their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. UBS Group lifted their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Tuesday, January 7th. Canaccord Genuity Group lifted their target price on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company upped their price target on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.